The role of angiotensin II (Ang II)-receptors on mitogen-activated protein kinase (MAPK) activation in cardiomyocytes remains controversial. Therefore, the current study was designed to investigate the actions of AT 1 -and AT 2 -receptors on Ang II-induced extracellular signal-regulated kinase (ERK), p38 and the c-Jun N-terminal kinase (JNK) MAPK activities in human cardiomyocytes. Human cardiac tissue was obtained from open-heart surgery (n=6). The cardiac tissue was minced and incubated in the special tissue culture system for 24 hours in the absence or presence of Ang II (10 -7 M). These studies were repeated with the AT 1 -receptor antagonist losartan (10 -6 M) or the AT 2 -receptor antagonist PD-123319 (10 -6 M). Immunohistochemical staining and Western blot analysis with phospho-antibodies were performed to determine ERK, JNK and p38 activities. Ang II increased ERK and p38 activities in human cardiomyocytes. The effects of Ang II were abolished by losartan and enhanced by PD-123319. Co-incubation with both losartan and PD-123319 resulted in a decrease of ERK and p38 activities in cardiomyocytes. The immunohistochemical staining of JNK showed no significant differences between Ang II alone, Ang II plus losartan and Ang II plus PD-123319 groups. In conclusion, Ang II has a potent effect on ERK and p38 MAPK activities in cardiomyocytes, by acting through AT 1 -receptors. This effect of Ang II is modified by AT 2 -receptors. Therefore, Ang II, via AT 1 -and AT 2 -receptor stimulation, has a distinct effect on MAPK activity in cardiomyocytes.
Introduction
Augmentation of angiotensinogen or angiotensinconverting enzyme (ACE) 1,2 and angiotensin II (Ang II) receptor mRNAs [3] [4] [5] [6] [7] [8] has been reported in association with cardiac hypertrophy and acute myocardial infarction (MI), suggesting that a cardiac renin-angiotensin system (RAS) is activated in cardiac remodelling. Two Ang II receptor subtypes, AT 1 and AT 2 , have been identified by ligand binding studies with non-peptide Ang II antagonists. 9, 10 To date, most of the well-known functions of Ang II in the cardiovascular system are mediated by the AT 1 -receptor. However, there is little information regarding the physiological roles of the AT 2 -receptor and its signal transduction pathway. 11, 12 Previous studies have reported that the AT 2 -receptor associates with G i proteins 13 and mediates the inhibitory effects of mitogen-activat-ed protein kinase (MAPK) activation in vascular smooth muscle cells (VSMC), 14 PC12W cells, 15 and neuronal cultures. 16 There are at least four major MAPK cascades in mammalian cells: the extracellular signal-regulated kinases 1 and 2 (ERK1/2 or p42/44 MAPK), the c-Jun N-terminal kinases (JNK), p38 MAPK, and big MAPK1 (BMK1 or ERK5). [17] [18] [19] [20] [21] Ang II can activate ERKs in VSMCs, 22 and very recent studies have shown that Ang II can also activate JNK and p38 MAPKs. [23] [24] [25] To date, the precise actions of Ang II in cardiomyocyte MAPK activation remain controversial. Based upon previous studies, we hypothesise that Ang II enhances MAPK activation through AT 1 -receptor stimulation, whereas AT 2 -receptor stimulation attenuates MAPK activities in human cardiomyocytes. Therefore, the present study was designed to investigate the role of AT 1 -and AT 2 -receptors on Ang II-mediated MAPK activation in human cardiomyocytes.
Methods

Human subjects and cardiac tissue incubation
This study was performed with the approval of the Institutional Review Board at the University of Maryland School of Medicine. Specimens of human atrial tissue (n=6) were obtained from patients undergoing coronary bypass surgery.The mean age of the patients (±SEM) was 62±3 years (range 51 to 75 years). All atrial specimens were grossly normal at the time of excision, and patients were free of supraventricular arrhythmia.
After cardiac tissue excision, the samples were immediately placed in oxygenated, nominally Ca 2+free Tyrode solution for transport to the laboratory. The tissues were chopped with scissors into cubic chunks (0.5 mm 3 ) in nominally Ca 2+ -free Tyrode solution (36°C). The Tyrode solution contained (mmol/L) NaCl 126.0, KCl 5.4, MgCl 2 1.0, NaH 2 PO 4 0.33, glucose 10.0, and HEPES 10.0, pH 7.4. The tissues then were placed in the special tissue culture system with 5% serum and culture medium (Clontech Laboratories, Inc., San Diego, CA) for 24 hours. As a negative control, we also investigated the TUNEL staining in fresh human myocardium without incubation. Cardiac samples from each patient were divided into seven study groups: [1] control (vehicle group); [2] Ang II alone (10 -7 M); [3] Ang II with losartan (10 -6 M); [4] Ang II with PD-123319 (10 -6 M); [5] Ang II with both losartan and PD-123319; [6] losartan alone; and [7] PD-123319 alone.After incubation, the car-diac tissues were immediately fixed with 10% buffered formalin for further studies.
The cardiac tissue viability was determined by the following methods: [1] staining with anti-alpha-1 antitrypsin antibody, anti-kappa light chain antibody and anti-lambda light chain antibody; [2] plasma membrane marker ouabain-sensitive Na + , K + -ATPase activities; [3] RNA quality, judging from 28S/18S ratio of rRNA and GAPDH mRNA; [4] tetrazolium derivative reduction (MTT) assay; [5] electron microscopy; [6] TUNEL staining and DNA gel electrophoresis. Our previous studies demonstrated that, using all of these evaluations, there were no significant differences between fresh cardiac tissue and cardiac tissue after 24-hours incubation. 26 This established the reliability of our tissue culture system, which should not significantly influence the results of our experiments.
Immunohistochemical staining (IHCS)
Immunohistochemical staining (IHCS) was performed as we have previously described. 26, 27 Briefly, human cardiac tissue was fixed in 10% formalin and embedded in paraffin. Serial sections were prepared at a thickness of 5 µm.Tissue sections were de-paraffinised and treated with 3% hydrogen peroxide. The sections were immunostained by a modified, two-stage protocol with primary phospho-p44/42 ERK antibody, phospho-SAPK/JNK antibody, phospho-p38 MAPK antibody (New England BioLabs, Inc.) and AT 1 -and AT 2receptor antibodies. Normal rabbit serum was substituted for the primary antibody in negative controls. The sections were reviewed with an Olympus microscope. Two trained independent observers reviewed these sections without any knowledge as to the respective group(s) from which the tissue was harvested.The result of IHCS was evaluated by IHCS density scores (0, no staining; 1, mini-mal staining; 2, mild staining; 3, moderate staining; and 4, strong staining). The positive staining area (+%) in the entire section was also determined.
Western blot analysis
Western blot analysis was performed as previously described. 27, 28, 29, 30 Briefly, the membranes were solubilised with 10 mM CHAPS, the purified antibody probe (20 µg), subjected to 7.5% SDS-PAGE, and electro-transferred to a nitrocellulose membrane. The nitrocellulose membrane was treated overnight at 4°C with antibodies, then washed and treated with goat anti-rabbit IgG peroxidase. The nitrocellulose membrane was washed and the immunoreactive bands were visualised using 4chloro-1-naphthol and hydrogen peroxide.
Statistics
Results of the quantitative studies are expressed as means±SEM. Statistical comparisons within each group were performed using analysis of variance (ANOVA) for repeated measures followed by Fisher's least significant difference test of repeated measures. Statistical comparisons between groups were performed using factorial ANOVA followed by Fisher's least significant difference test of repeated measures. Statistical significance was accepted at p<0.05. Figures 1A and 1B ,both AT 1 -and AT 2 -receptors were prominent in human myocardium.The sections treated with pre-absorbed specific AT 1 antiserum ( Figure 1D ) or AT 2 antiserum ( Figure 1E ), instead of primary antibody, demonstrated no immunoperoxidase activity. Furthermore, sections stained with myosin, which is a marker of cardiomyocytes, indicated that both AT 1 -and AT 2 -receptors The phosphorylation of ERK immunohistochemical staining in a representative human myocardium.The ERK was positively stained in nuclear, perinuclear and cytoplasm region of cardiomyocytes.There was mild staining of ERK in the control group (A). In contrast,Ang II significantly increased ERK positive staining density in myocardium (B, arrow). Furthermore, co-incubation of Ang II with losartan significantly attenuated ERK activity in cardiomyocytes (C). On the other hand, PD-123319 enhanced Ang II-mediated ERK activity in myocardium (D, arrow). Co-incubation of Ang II with both losartan and PD-123319 (E) significantly decreased ERK immunohistochemical staining in human myocardium. Figure  F illustrates a negative control with normal rabbit serum (NRS) instead of the primary antibody which indicated no staining in those specimens (Original magnification x1000).
Results
IHCS illustrated the expression and localisation of AT 1 -and AT 2 -receptors in human cardiomyocytes.As shown in
Figure 3
The immunohistochemical staining of p38 phosphorylation in a representative human myocardium.The phosphorylation of p38 immunoreactivity was found in the nuclear, perinuclear and cytoplasm region of cardiomyocytes. In the control group, there was mild staining of p38 (A). In contrast, significant enhancement of p38 staining density was found in myocardium in the Ang II group (B, arrow). In the angiotensin II with losartan group, there is significant attenuation of p38 activity in cardiomyocytes (C). In contrast, p38 staining density was significantly increased in the Ang II plus PD-123319 group in cardiomyocytes (D, arrow).There was a significant decrease of p38 immunohistochemical staining in human myocardium in co-incubation of Ang II with both losartan and PD-123319 (E). Figure F 3F and 4F ).There were no significant differences in ERK, p38 and JNK IHCS scores between the losartan or PD-123319 alone groups and the control group.
Western blot analysis demonstrated that ERK and p38 activities were significantly increased in the Ang II alone group in cardiomyocytes, compared with the control group ( Figure 5 ). In the Ang II plus losartan group, both ERK and p38 phosphorylations were significantly decreased. Further-more, ERK and p38 activities were markedly increased in the Ang II PAPER Figure 4 The immunohistochemical staining of JNK phosphorylation in human cardiomyocytes illustrated that positive staining density of phospho-JNK was located in nuclear, perinuclear and cytoplasm region of cardiomyocyte.There were no significant differences of positive staining density of JNK in cardiomyocytes among Ang II alone,Ang II with losartan or Ang II with PD-123319 groups (Figure A to E, Original magnification x1000) . Figure F is a negative control with normal rabbit serum (NRS) (Original magnification x1000). plus PD-123319 group. In the Ang II plus both losartan and PD-123319 group, ERK and p38 activities were significantly decreased to control levels. In contrast, there was no significant difference of JNK activity in each study group ( Figure 5 ). In the losartan or PD-123319 alone groups, the levels of ERK, p38 and JNK were not significantly different compared with the control group.
Discussion
The present study demonstrates that Ang II, via AT 1 -receptor activation, increases ERK and p38 activities in human cardiomyocytes, with no significant change in JNK immunoreactivity. Furthermore, Ang II, via the AT 2 -receptor, has potent inhibitory effects on ERK and p38 activities in cardiomyocytes. Co-inhibition of both losartan and PD-123319 resulted in a significant decrease of ERK and p38 activities in human cardiomyocytes. Immunohistochemical staining of JNK was not markedly changed in cardiomyocytes in the Ang II with losartan and PD-123319 groups. High-affinity Ang II binding sites are found in neonatal and adult cardiomyocytes and fibroblasts of many species. 31, 32 Two Ang II receptor subtypes, AT 1 and AT 2 , have been identified by ligand binding studies with non-peptide Ang II antagonists. 9, 10 The AT 1 -receptor is selectively blocked by losartan, and the AT 2 -receptor is selectively blocked by PD-123319. 9, 10 Ang II has direct short-term cardiac actions that include increased contractility and calcium gradient. Ang II also has long-term structural effects on the heart, through its direct hypertrophic growth action on cardiomyocytes and stimulation of collagen and connective tissue biosynthesis by fibroblasts. 33, 34 The MAPKs have been implicated in cardiomyocyte and VSMC proliferation, hypertrophy, and differentiation, key responses in the pathology of cardiovascular diseases such as hypertension, congestive heart failure, left ventricular hypertrophy and atherosclerosis. 35 Recent studies have demonstrated JNK and p38 MAPK activation with both cellular growth and apoptosis. 29, 30, 36 Activated ERKs can translocate to the nucleus and lead to the phosphorylation and activation of transcriptional factors, such as Elk-1, Sap-1, c-fos, and CREB. 37 JNK can phosphorylate and activate transcription factors such c-Jun and ATF-2, whereas p38 MAPK can activate transcriptional factors such as ATF-2 and CREB. [37] [38] [39] [40] The ERK, JNK, and p38 signalling cascades run in parallel with distinct upstream activators. However, there can be cross-talk and crossactivation. Ang II can activate ERKs in VSMC, 22, 41 and recent studies have shown that Ang II can also activate JNK and p38 MAPKs. [23] [24] [25] The current study demonstrated that Ang II increases ERK and p38 MAPK activities, but not JNK levels, in cardiomyocytes. However, since JNK might increase within minutes, the maximal level of JNK after Ang II stimulation in myocardium might have been missed. Further studies are required to investigate the time course of Ang II-mediated MAPK activities in human cardiac tissue.The results from the present study clearly demonstrate that Ang II, via AT 1 -receptor activation, increases ERK and p38 MAPK activities in cardiomyocytes.These data suggest that Ang II, through Ang II receptors, plays an important role in regulation of intracellular signalling pathways and in modulation of cardiac remodelling and cardiac function.
The apparent relationship between the AT 1receptor level and cardiac function may be explained, either by the direct effect of the AT 1receptor on cardiac contractility, or by the downregulation of the AT 1 -receptor in the failing myocardium, due to increased plasma Ang II levels. Blockade of the AT 1 -receptor may result in the shunting of Ang II to the AT 2 -receptor. More recent studies have demonstrated that the AT 2 -receptor decreases AT 1 -receptor-mediated ERK activity in VSMC. 14 In cells expressing AT 1 -receptors, Ang II activates ERK, which leads to a mitogenic or hypertrophic response through activation of the tyrosine kinase system. 42,43 AT 2 -receptors were shown to have an inhibitory effect on the AT 1receptor-mediated growth-promoting action, assessed by DNA synthesis in coronary endothelial cells or VSMC. 14,44 AT 2 -receptor stimulation inhibits AT 1 -receptor-mediated DNA and cell growth in cardiomyocytes 45 or fibroblasts from myopathic hamsters. 46 The current study indicated that Ang II, via the AT 1 -receptor, increases ERK and p38 activities in cardiomyocytes. In contrast, AT 2 -receptor stimulation results in significant inhibition of ERK and p38 expression in human cardiomyocytes. AT 2 -receptor-mediated inhibition of serum-or growth factor-induced ERK activity in NIE-115 cells is associated with vanadate-sensitive PTP, in which catalytic activity of Src homology 2 domain phosphatase-1 (SHP-1), a soluble PTP, is an early transducer of the AT 2 -receptor signalling pathway. 47 Previous studies have demonstrated that AT 2 -receptors significantly inhibit AT 1 -receptormediated ERK activation in perfused mouse cardiac tissue overexpressing AT 2 -receptors. 12 The mechanism of AT 2 -receptor-mediated inhibition of the ERK pathway 11 might be associated with reduced ERK activity caused by the activation of ERK phosphatase 1 (MKP-1), a dual-specificity phosphatase that acts on both phosphotyrosine and phosphothreonine.
In summary, the present study demonstrated that Ang II induces ERK and p38 activities in human cardiomyocytes via the AT 1 -receptor. In contrast, AT 2 -receptor stimulation causes a significant decrease in ERK and p38 MAPK activities in cardiomyocytes.Therefore,Ang II, via AT 1 -and AT 2receptors in cardiomyocytes, may mediate distinct effects in the intracellular downstream signalling pathways and in the processes of cardiac hypertrophy, apoptosis and congestive heart failure.
